12.74

0.31% -0.04

After Hours: 12.74

Aurinia Pharmaceuticals Inc (AUPH)

Overview News Price History Option Chain Financials Why AUPH Down? Discussions Forecast Stock Split

Aurinia Pharmaceuticals Inc stock is traded at $12.74, with a volume of 1.37M. It is down -0.31% in the last 24 hours and up +12.54% over the past month. Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Previous Close:

$12.78

Open:

$12.72

24h Volume:

1.37M

Relative Volume:

0.69

Market Cap:

$1.68B

Revenue:

$260.11M

Net Income/Loss:

$60.64M

P/E Ratio:

29.63

EPS:

0.43

Net Cash Flow:

$92.29M

1W Performance:

+2.74%

1M Performance:

+12.54%

6M Performance:

+56.32%

1Y Performance:

+93.62%

1-Day Range:

$12.53

$12.87

1-Week Range:

$12.06

$12.87

52-Week Range:

$6.55

$12.87

Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile

Name

Aurinia Pharmaceuticals Inc

Sector

Healthcare (1152)

Industry

Biotechnology (648)

Phone

250-744-2487

Address

#140, 14315 - 118 AVENUE, EDMONTON, BC

Employee

300

Twitter

@AuriniaPharma

Next Earnings Date

2024-11-07

Latest SEC Filings

AUPH's Discussions on Twitter

Compare AUPH with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AUPH Aurinia Pharmaceuticals Inc	12.74	1.61B	260.11M	60.64M	92.29M	0.43
VRTX Vertex Pharmaceuticals Inc	394.53	99.62B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	465.89	61.52B	2.46B	-319.09M	-52.09M	-2.47
REGN Regeneron Pharmaceuticals Inc	560.00	58.91B	14.21B	4.46B	3.56B	39.68
ARGX Argen X Se Adr	756.38	46.69B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	324.34	34.54B	3.81B	-644.79M	-669.77M	-6.24

Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-30-25	Resumed	H.C. Wainwright	Buy
Nov-04-22	Downgrade	Oppenheimer	Outperform → Perform
May-05-22	Resumed	Cantor Fitzgerald	Overweight
Dec-10-21	Upgrade	Oppenheimer	Perform → Outperform
Oct-28-21	Downgrade	Oppenheimer	Outperform → Perform
Jan-25-21	Reiterated	H.C. Wainwright	Buy
Nov-03-20	Reiterated	H.C. Wainwright	Buy
Jun-17-20	Initiated	BTIG Research	Buy
May-05-20	Initiated	Cowen	Outperform
Jan-10-20	Initiated	Jefferies	Buy
Dec-16-19	Reiterated	H.C. Wainwright	Buy
Mar-16-18	Reiterated	Cantor Fitzgerald	Overweight
Feb-08-18	Initiated	RBC Capital Mkts	Outperform
Oct-30-17	Reiterated	H.C. Wainwright	Buy
May-18-17	Reiterated	H.C. Wainwright	Buy
Apr-11-17	Initiated	Cantor Fitzgerald	Overweight
Mar-22-17	Reiterated	FBR & Co.	Outperform
Dec-30-16	Reiterated	H.C. Wainwright	Buy
Aug-17-16	Reiterated	H.C. Wainwright	Buy
Jun-30-16	Initiated	H.C. Wainwright	Buy
May-08-15	Initiated	MLV & Co	Buy

View All

Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News

Sep 12, 2025

Ieq Capital LLC Invests $266,000 in Aurinia Pharmaceuticals Inc $AUPH - MarketBeat

Sep 12, 2025

Aurinia Pharmaceuticals stock hits 52-week high at 12.82 USD - Investing.com

Sep 12, 2025

Jacobs Levy Equity Management Inc. Buys 304,420 Shares of Aurinia Pharmaceuticals Inc $AUPH - MarketBeat

Sep 12, 2025

Vident Advisory LLC Acquires New Stake in Aurinia Pharmaceuticals Inc $AUPH - MarketBeat

Sep 12, 2025

Sep 10, 2025

Institutional Investors Have a Lot Riding on Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) With 50% Ownership - 富途牛牛

Sep 10, 2025

Sep 07, 2025

Are Strong Financial Prospects The Force That Is Driving The Momentum In Aurinia Pharmaceuticals Inc.'s NASDAQ:AUPH) Stock? - simplywall.st

Sep 07, 2025